Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report.

IF 5.3 2区医学 Q1 ONCOLOGY JCO precision oncology Pub Date : 2024-09-01 DOI:10.1200/PO.24.00228

Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, Yoshiyuki Ayada, Go Makimoto, Eiki Ichihara, Natsuko Okita, Shinichi Toyooka, Yoshinobu Maeda, Masahiro Tabata

引用次数: 0

Abstract

Imatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

KIT Q556_K558 框内缺失的胃腺癌患者对伊马替尼的反应：病例报告。

伊马替尼可能是一种有效的靶向药物，可用于KIT突变的晚期胃腺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

JCO precision oncology ONCOLOGY-

CiteScore

9.10

自引率

4.30%

发文量

363

期刊最新文献

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. Erratum: Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma. Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.